Ravel Biotechnology
Building a platform to unlock early detection of disease.
Building a platform to unlock early detection of disease.
Ravel Biotechnology is a biotechnology startup that has set out to revolutionize disease detection by developing a platform focused on early detection. Using epigenomic profiles, the company aims to detect the destruction of healthy and diseased cells, a common feature in all diseases, in cell-free DNA. Founded in 2018 and headquartered in the United States, Ravel Biotechnology received a notable Venture Round investment on 01 January 2020 from Hemi Ventures. With its pioneering approach and strong industry positioning in Analytics, Biotechnology, and Health Care, Ravel Biotechnology highlights its potential for growth and impact, presenting an attractive opportunity for venture capital investors looking to tap into the future of disease detection and healthcare innovation.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 |
|
01 Jan 2020 |
| Seed Round | Unknown | 1 |
|
23 Aug 2019 |
No recent news or press coverage available for Ravel Biotechnology.
We care about your data, and we'd love to use cookies make your experience better.
